Heart failure trials in Japan

20 of 25 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  Where

  Aichi, Kasugai, Azumino-shi, Chiba, Chiba, Chūōku, Fujisawa-shi, Fukuoka, Kitakyushu, Hachioji-shi, Hamada-Shi, Higashiibaraki-gun, Himeji-Shi, Hiratsuka-shi, Hokkaido, Sapporo, Hokkaido, Tomakomai, Hyogo, Amagasaki, Ikeda-cho, Kitaazumi, Ishikawa, Kanazawa, Iwakuni-shi, Kamakura-shi, Kanagawa, Miura-gun, Kanagawa, Yokohama, Kanonji-shi, Kawanishi-shi, Kishiwada-shi, Kobe, Kumamoto, Matsumoto-shi, Matsuyama, Mito, Nakano-shi, Ōita, Okayama, Okayama, Okinawa, Naha, Okinawa, Urasoe, Osaka, Osaka, Osaka, Saga, Saitama-shi, Sendai, Suita-shi, Tachikawa-shi, Takamatsu, Tokushima, Tokyo, Ome, Tomakomai-shi

  Age

  18 years and over

  People

  6,712 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT06424288 · EU 2023-509706-30-00
• Phase 3Taking people
  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  Where

  Amagasaki-shi, Asahi-shi, Fujisawa-shi, Fukuoka, Fukuoka, Chikushino, Gunma, Maebashi, Hachioji-shi, Hamada-Shi, Hamamatsu, Himeji-Shi, Hiratsuka-shi, Hitachi-Naka, Ishikawa, Kanazawa, Iwakuni-shi, Kamakura-shi, Kanagawa, Miura-gun, Kanonji-shi, Kasama-Shi, Kasugai-shi, Kawaguchi-shi, Kawasaki-shi, Kishiwada-shi, Kobe, Kumamoto, Kure, Matsudo-shi, Matsumoto-shi, Matsuyama, Meguro-Ku, Mito, Miyagi, Sendai, Nagasaki, Nagasaki, Nagoya, Nakano-shi, Nara, Kashihara, Okayama, Okayama, Ome-shi, Omura-shi, Osaka, Saitama, Saitama, SakaiShi, Sapporo, Sendai, Shimonoseki-shi, Suita-shi, Suita-Shi, Tachikawa-shi, Takasaki-shi, Tanabe-shi, Tokushima, Tomakomai-shi, Toyota-shi, Ueda-shi

  Age

  18 years and over

  People

  4,200 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT06935370 · EU 2024-519525-38-00
• Phase 2Taking people
  The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)

  Where

  Nagoya, Ōbu, Tokyo, Tsu

  Age

  26 years and over

  People

  90

  Run by

  Nagoya University

  See details and how to joinNCT07855692
• Phase 1Not yet taking people in Japan
  A Study of LY3971297 in Participants With Heart Failure

  Where

  Kobe, Kyoto, Suita-Shi, Tsuchiura-shi

  Age

  18 years to 65 years

  People

  90 worldwide

  Run by

  Eli Lilly and Company

  See details and how to joinNCT07547540 · EU 2026-525663-40-00
• No phaseTaking people
  ELEVATE-HFpEF Clinical Study

  Where

  Chiba, Kitakyushu, Suita

  Age

  40 years and over

  People

  700 worldwide

  Run by

  Medtronic Cardiac Rhythm and Heart Failure

  See details and how to joinNCT06678841
• Phase 3Taking people
  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  Where

  Chiba, Fujinomiya-shi, Fukuoka, Hachioji-shi, Hamamatsu, Higashiyamato-shi, Himeji-Shi, Kagoshima, Kanazawa, Kitaazumi-gun, Kitakyushu-shi, Kumamoto, Kyoto, Niigata, Ōita, Sagamihara-shi, Sapporo, Shinagawa-ku, Suginami-ku, Suita-shi, Takamatsu, Takarazuka-shi, Toyoake-shi, Yonago-shi

  Age

  18 years to 99 years

  People

  5,056 worldwide

  Run by

  Amgen

  See details and how to joinNCT07037459
• Phase 2Taking people
  A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)

  Where

  Iwakuni, Kasugai, Kishiwada, Kodaira-shi, Koga, Matsudo, Meguro-Ku, Nagasaki, Sagamihara, Sapporo, Sendai, Suginami, tabashi City, Toshimaku, Tsu, Wako, Yokohama

  Age

  18 years to 79 years

  People

  620 worldwide

  Run by

  Pfizer

  See details and how to joinNCT06991257 · EU 2024-518438-94-00
• Phase 1/2Taking people
  Endocardial Delivery for Myocardial Regeneration Using Allogeneic iPSC-derived Cardiomyocyte Spheroids for HF With Systolic Dysfunction (EMERALD Study)

  Where

  Kawasaki, Matsumoto, Shinagawa Ku, Shinjuku-ku, Tsukuba

  Age

  20 years to 80 years

  People

  14

  Run by

  Heartseed Inc.

  See details and how to joinNCT07347197
• Phase 3Taking people
  Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  Where

  Amagasaki-shi, Asahikawa-shi, Azumino-shi, Chūōku, Fukui-shi, Hakusan-shi, Himeji, Izumo-shi, Kakegawa-shi, Kamakura-shi, Kanazawa, Kawaguchi-shi, Kishiwada-shi, Kita-ku, Kyoto, Matsudo-shi, Meguro-ku, Mito, Miyazaki, Nagano, Ogaki-shi, Ōita, Ōmihachiman, Osaka, Saitama-shi, Sendai, Shizuoka, Suita-shi, tabashi City, Takamatsu, Takatsuki-shi, Toyota-Shi, Tsuchiura-shi, Ueda-shi, Uwajima-shi, Yanagawa-shi, Yokkaichi-shi, Yokohama

  Age

  40 years and over

  People

  11,300 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06677060 · EU 2024-514506-32-00
• Phase 3Taking people
  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  Where

  Amagasaki, Bunkyo-ku, Fukuoka, Himeji, Kanagawa, Kashihara, Kitakyushu, Kobe, Kumamoto, Kurume-shi, Kyoto, Matsumoto, Nagasaki, Nagoya, Nankoku-shi, Osaka, Sapporo, Suita, Tokyo, Toyama, Tsu, Uwajima-shi, Yamaguchi Prefecture, Yokohama

  Age

  18 years and over

  People

  1,280 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT07207811
• Phase 2Taking people
  Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

  Where

  Kamakura, Kasugai, Matsubara, Matsudo

  Age

  18 years to 80 years

  People

  180 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT07830719 · EU 2026-525974-21-00
• Phase 3Taking people
  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  Where

  Beppu-shi, Bunkyō City, Fujisawa-shi, Fukui-shi, Fukuoka, Fukutsu-shi, Hakusan-shi, Higashiibaraki-gun, Himeji, Iwakuni-shi, Kanazawa, Kanonji-shi, Kasugai-shi, Kasuga-shi, Kawaguchi, Kawanishi-shi, Kishiwada-shi, Kitakyusyu-shi, Kobe, Kochi, Kure-shi, Maebashi, Matsumoto-shi, Meguro-ku, Mito, Moriyama-shi, Nagoya, Ōita, Osaka, Sagamihara-shi, Saitama-shi, Sakaishi, Sakata, Sanyoonoda-shi, Toshima-ku, Toyota, Tsuchiura-shi, Ueda-shi, Uji-shi, Uwajima-shi, Yanagawa-shi, Yokohama

  Age

  18 years to 130 years

  People

  3,850 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06307652 · EU 2023-508162-15-00
• Phase 2Taking people
  A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

  Where

  Bunkyo-ku, Tokyo, Chikushino-shi, Fukuoka, Himeji-shi, Hyogo, Ibaraki, Kagawa, Kanagawa, Kita-gun, Kagawa, Kobe-shi, Hyogo, Ome-shi, Tokyo, Osaka-shi, Osaka, Osaka-Shi, Osaka, Sapporo-shi, Hokkaido, Yokohama-shi, Kanagawa

  Age

  40 years to 84 years

  People

  200 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT06979362 · EU 2024-515796-35-00
• Phase 3Taking people
  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  Where

  Aomori, Chikushino-shi, Chūōku, Fukui-shi, Fukushima, Higashiibaraki-gun, Higashiohmi-shi, Iwakuni-shi, Kagoshima, Kamakura-shi, Kanazawa, Kashihara-shi, Kasugai-shi, Kawagoe-shi, Kishiwada-shi, Kitakyusyu-shi, Kobe, Kure-shi, Kyoto, Maebashi, Matsusaka-shi, Minatoku, Mito, Morioka, Nagasaki, Nagoya, Ōmihachiman, Osaka, Sagamihara-shi, Sapporo, Sayama-shi,, Sendai, Shibuya-ku, Shizuoka, Suginami City, Suita, Suzuka-shi, Tachikawa-shi, Takaoka-shi, Takatsuki-shi, Tokushima, Toshima-ku, Toyama, Ueda-shi, Urasoe-Shi, Urayasu-shi, Uruma, Utsunomiya, Wakayama, Yakushi, Yokohama

  Age

  18 years and over

  People

  6,950 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07761117 · EU 2026-526304-79-00
• Phase 3Taking people
  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  Where

  Bunkyo-ku, Tokyo, Chiba-shi,Chiba, Chikushino-shi, Fukuoka, Fuchu-shi,Tokyo, Fukuoka-shi, Fukuoka, Higashiosaka-shi, Osaka, Himeji-shi, Hyogo, Hyōgo, Ibaraki, Kanagawa, Kasugai-shi, Aichi, Kofu-shi, Yamanashi, Kyoto-shi, Kyoto, Maebashi-shi, Gunma, Matsumoto-shi, Nagano, Miura-gun, Kanagawa, Morioka-shi, Iwate, Nagasaki, Osaka, Osaka-Shi, Osaka, Ota-shi, Gunma, Sapporo-shi, Hokkaido, Shinjuku-ku, Tokyo, Shizuoka, Takamatsu-shi, Kagawa, Tokyo, Tomakomai-Shi, Hokkaido, Toshima-ku,Tokyo, Uwajima-shi, Wakayama-shi, Wakayama, Yokohama-shi，Kanagawa

  Age

  18 years and over

  People

  5,610 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT07567001 · EU 2025-523717-29-00
• Phase 4Taking people
  Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure

  Where

  Fukuoka, Handa, Iizuka, Izunokuni, Kakegawa, Kawagoe, Maebashi, Nagoya, Ōbu, Osaka, Sagamihara, Sakai, Sapporo, Suita, Takasaki, Tokyo, Tōon, Toyota

  Age

  18 years and over

  People

  550

  Run by

  Juntendo University

  See details and how to joinNCT07397650
• Phase 3Taking people
  A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

  Where

  Isehara, Iwakuni, Kyoto, Osaka, Ōta-ku, Sagamihara, Sapporo, Sendai, Suita

  Age

  18 years and over

  People

  2,600 worldwide

  Run by

  Colorado Prevention Center

  See details and how to joinNCT06033950
• Phase 2Taking people
  Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG

  Where

  Osaka

  Age

  18 years to 80 years

  People

  50

  Run by

  Rohto Pharmaceutical Co., Ltd.

  See details and how to joinNCT07192211
• Phase 2Taking people
  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  Where

  Bunkyo-ku, Tokyo, Hamamatsu-shi, Shizuoka, Himeji-shi, Hyogo, Ibaraki, Kanagawa, Kita-gun, Kagawa, Kobe-shi, Hyogo, Osaka, Osaka-shi, Osaka, Osaka-Shi, Osaka, Sapporo-shi, Hokkaido, Yokohama-shi, Kanagawa

  Age

  40 years to 84 years

  People

  200 worldwide

  Run by

  Novo Nordisk A/S

  See details and how to joinNCT06979375 · EU 2024-515797-27-00
• Phase 3Taking people
  Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

  Where

  Adachi City, Anjo, Chikushino-shi, Chiyoda City, Fuchū, Fukuoka, Funabashi, Gifu, Hachiōji, Hamamatsu, Hirosaki, Hiroshima, Hokkaido, Isehara, Izunokuni, Kamakura, Kamogawa, Kanagawa, Kashihara, Kasukabe, Kawagoe, Kawaguchi, Kawasaki, Kochi, Kurume, Kushiro, Maebashi, Minato, Morioka, Nagakute, Nagoya, Nankoku, Nara, Ōgaki, Okayama, Okinawa, Osaka, Saitama, Sapporo, Sayama, Shinjuku, Sōka, Suita, Sumoto, Tachikawa, Tokushima, Tokyo, Tsuchiura, Urasoe, Urayasu, Utsunomiya, Yokohama

  Age

  20 years and over

  People

  444

  Run by

  Juntendo University

  See details and how to joinNCT05392764